937 related articles for article (PubMed ID: 26644172)
1. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM; Hoppe CC; Abboud MR; Inusa B; Kanter J; Ogutu B; Brown PB; Heath LE; Jakubowski JA; Zhou C; Zamoryakhin D; Agbenyega T; Colombatti R; Hassab HM; Nduba VN; Oyieko JN; Robitaille N; Segbefia CI; Rees DC;
N Engl J Med; 2016 Feb; 374(7):625-35. PubMed ID: 26644172
[TBL] [Abstract][Full Text] [Related]
2. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
[TBL] [Abstract][Full Text] [Related]
3. Prasugrel for Sickle Cell Vaso-Occlusive Events.
Badawy SM
N Engl J Med; 2016 Jul; 375(2):185. PubMed ID: 27410931
[No Abstract] [Full Text] [Related]
4. Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM; Hoppe CC; Rees DC
N Engl J Med; 2016 Jul; 375(2):185-6. PubMed ID: 27410930
[No Abstract] [Full Text] [Related]
5. Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.
Heeney MM; Abboud MR; Githanga J; Inusa BPD; Kanter J; Michelson AD; Nduba V; Musiime V; Apte M; Inati A; Taksande AM; Andersson M; Åstrand M; Maklad N; Niazi M; Himmelmann A; Berggren AR
Blood; 2022 Sep; 140(13):1470-1481. PubMed ID: 35849650
[TBL] [Abstract][Full Text] [Related]
6. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.
Jakubowski JA; Hoppe CC; Zhou C; Smith BE; Brown PB; Heath LE; Inusa B; Rees DC; Small DS; Gupta N; Yao S; Heeney M; Kanter J
Thromb Haemost; 2017 Feb; 117(3):580-588. PubMed ID: 27929203
[TBL] [Abstract][Full Text] [Related]
7. Prasugrel hydrochloride for the treatment of sickle cell disease.
Conran N; Rees DC
Expert Opin Investig Drugs; 2017 Jul; 26(7):865-872. PubMed ID: 28562105
[TBL] [Abstract][Full Text] [Related]
8. Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia.
Heath LE; Heeney MM; Hoppe CC; Adjei S; Agbenyega T; Badr M; Masera N; Zhou C; Brown PB; Jakubowski JA; Dampier C
Clin Trials; 2017 Dec; 14(6):563-571. PubMed ID: 28743191
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet agents for preventing vaso-occlusive events in people with sickle cell disease: a systematic review.
Martí-Carvajal A; Abd El Aziz MA; Martí-Amarista C; Solà I
Clin Adv Hematol Oncol; 2019 Apr; 17(4):234-243. PubMed ID: 31188815
[TBL] [Abstract][Full Text] [Related]
10. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI; Kutlar A; Kanter J; Liles D; Cancado R; Friedrisch J; Guthrie TH; Knight-Madden J; Alvarez OA; Gordeuk VR; Gualandro S; Colella MP; Smith WR; Rollins SA; Stocker JW; Rother RP
N Engl J Med; 2017 Feb; 376(5):429-439. PubMed ID: 27959701
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
[TBL] [Abstract][Full Text] [Related]
12. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Biemond BJ; Tombak A; Kilinc Y; Al-Khabori M; Abboud M; Nafea M; Inati A; Wali Y; Kristensen J; Kowalski J; Donnelly E; Ohd J;
Lancet Haematol; 2021 May; 8(5):e334-e343. PubMed ID: 33894169
[TBL] [Abstract][Full Text] [Related]
13. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease.
Weiner DL; Hibberd PL; Betit P; Cooper AB; Botelho CA; Brugnara C
JAMA; 2003 Mar; 289(9):1136-42. PubMed ID: 12622584
[TBL] [Abstract][Full Text] [Related]
14. Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
Casella JF; Barton BA; Kanter J; Black LV; Majumdar S; Inati A; Wali Y; Drachtman RA; Abboud MR; Kilinc Y; Fuh BR; Al-Khabori MK; Takemoto CM; Salman E; Sarnaik SA; Shah N; Morris CR; Keates-Baleeiro J; Raj A; Alvarez OA; Hsu LL; Thompson AA; Sisler IY; Pace BS; Noronha SA; Lasky JL; de Julian EC; Godder K; Thornburg CD; Kamberos NL; Nuss R; Marsh AM; Owen WC; Schaefer A; Tebbi CK; Chantrain CF; Cohen DE; Karakas Z; Piccone CM; George A; Fixler JM; Singleton TC; Moulton T; Quinn CT; de Castro Lobo CL; Almomen AM; Goyal-Khemka M; Maes P; Emanuele M; Gorney RT; Padgett CS; Parsley E; Kronsberg SS; Kato GJ; Gladwin MT
JAMA; 2021 Apr; 325(15):1513-1523. PubMed ID: 33877274
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3).
Heeney MM; Abboud MR; Amilon C; Andersson M; Githanga J; Inusa B; Kanter J; Leonsson-Zachrisson M; Michelson AD; Berggren AR;
Contemp Clin Trials; 2019 Oct; 85():105835. PubMed ID: 31446143
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adenotonsillectomy in reducing obstructive sleep apnea, cerebrovascular ischemia, vaso-occlusive pain, and ACS episodes in pediatric sickle cell disease.
Tripathi A; Jerrell JM; Stallworth JR
Ann Hematol; 2011 Feb; 90(2):145-50. PubMed ID: 20714723
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.
Moser BA; LaBell ES; Chigutsa E; Jakubowski JA; Small DS
Clin Pharmacokinet; 2018 Feb; 57(2):243-254. PubMed ID: 28578536
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
Wun T; Soulieres D; Frelinger AL; Krishnamurti L; Novelli EM; Kutlar A; Ataga KI; Knupp CL; McMahon LE; Strouse JJ; Zhou C; Heath LE; Nwachuku CE; Jakubowski JA; Riesmeyer JS; Winters KJ
J Hematol Oncol; 2013 Feb; 6():17. PubMed ID: 23414938
[TBL] [Abstract][Full Text] [Related]
19. Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease.
Goldman RD; Mounstephen W; Kirby-Allen M; Friedman JN
Pediatrics; 2013 Dec; 132(6):e1634-41. PubMed ID: 24276838
[TBL] [Abstract][Full Text] [Related]
20. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
